Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P46976
UPID:
GLYG_HUMAN
Alternative names:
-
Alternative UPACC:
P46976; D3DNH0; D3DNH1; D3DNH2; Q6FHZ1; Q9UNV0
Background:
Glycogenin-1 plays a pivotal role in glycogen biosynthesis. It self-glucosylates to form an oligosaccharide primer, serving as a substrate for glycogen synthase. This process is crucial for the proper storage and utilization of glucose, impacting energy metabolism in muscle and other tissues.
Therapeutic significance:
Glycogenin-1 is implicated in Glycogen storage disease 15 and Polyglucosan body myopathy 2, disorders characterized by muscle weakness and abnormal glycogen accumulation. Understanding the role of Glycogenin-1 could open doors to potential therapeutic strategies for these metabolic disorders.